The US Food and Drug Administration (FDA) has granted fast-track designation to Opexa Therapeutics’ Tovaxin drug candidate, used to treat secondary progressive multiple sclerosis.

The fast-track status will facilitate to develop and expedite the review of drugs intended to treat serious or life-threatening conditions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Fast-track priority review products are expected to be approved during the first review cycle, resulting in a halved review period compared to those without the designation.

Opexa president and CEO Neil Warma said the receipt of fast-track designation will advance Tovaxin through the clinical and regulatory process.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now